Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Nolasco (Catania, Italy), C. Crimi (Catania, Italy), R. Campisi (Catania, Italy), G. Cacopardo (Catania, Italy), R. Intravaia (Catania, Italy), M. Porto (Catania, Italy), N. Crimi (Catania, Italy). Rapid Benralizumab effectiveness in patients with severe eosinophilic asthma and bronchiectasis. 2225

Member's Comments

No comment yet.

Related content which might interest you: Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Prevalence of non-cystic fibrosis bronchiectasis in patients with severe asthma: a real-life study Source: Virtual Congress 2020 – Air pollution and comorbidities Year: 2020 Late-onset persistent eosinophilic severe asthma Source: International Congress 2015 – Severe asthma phenotyping Year: 2015 Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Mepolizumab in real-life treatment of severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 The importance of eosinophilic inflammation in COPD exacerbations Source: International Congress 2017 – COPD management Year: 2017 Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Effect of anti-IL5 treatment on symptoms of chronic rhinosinusitis, otitis and hearing loss in patients with severe eosinophilic asthma Source: International Congress 2019 – Clinical approach to asthma management Year: 2019 Improved small airway function by benralizumab in patients with severe eosinophilic asthma Source: Virtual Congress 2020 – From respiratory physiology to clinical practice: exercise and respiratory muscles Year: 2020 Assessing response to treatment of exacerbations of bronchiectasis in adults Source: Eur Respir J 2009; 33: 312-318 Year: 2009 Benralizumab for severe asthma associated with extra-airway eosinophilic diseases Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Idiopathic chronic eosinophilic pneumonia and asthma: how do they influence each other? Source: Eur Respir J 2003; 22: 8-13 Year: 2003 Role of non-cystic fibrosis bronchiectasis in hospitalized patients with acute exacerbation of COPD Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies? Year: 2017 Heterogeneous response of airway eosinophilia to biologics in severe asthma patients Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Clinical outcome of eosinophilic airway inflammation in chronic airway diseases including nonasthmatic eosinophilic bronchitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Predictors of sputum eosinophilia in severe asthma Source: Virtual Congress 2020 – Clinical parameters in severe asthma Year: 2020 A study on the pulmonary function of patients with chronic eosinophilic pneumonia Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 Benralizumab efficacy in patients with uncontrolled eosinophilic asthma by age at diagnosis Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018